SLC5A2 and type 2 diabetes mellitus: Regarding safety, the incidence of serious adverse events from SGLT-2 inhibitors as an add-on treatment for metformin, both in Asian and non-Asian T2DM patients, indicated no significant change compared with metformin monotherapy.